Publications on UniCAR/RevCAR Platforms

Albert S, Koristka S, Gerbaulet A, Cartellieri M, Arndt C, Feldmann A, et al. Tonic Signaling and Its Effects on Lymphopoiesis of CAR-Armed Hematopoietic Stem and Progenitor Cells. J Immunol. 2019, 202(6):1735-1746. doi: 10.4049/jimmunol.1801004.

Loureiro LR, Feldmann A, Bergmann R, Koristka S, Berndt N, Arndt C, et al. Development of a novel target module redirecting UniCAR T cells to Sialyl Tn-expressing tumor cells. Blood Cancer J. 2018, 8(9):81. doi: 10.1038/s41408-018-0113-4.

Koristka S, Kegler A, Bergmann R, Arndt C, Feldmann A, Albert S, et al. Engrafting human regulatory T cells with a flexible modular chimeric antigen receptor technology. J Autoimmun. 2018, 90:116-131. doi: 10.1016/j.jaut.2018.02.006.

Albert S, Arndt C, Koristka S, Berndt N, Bergmann R, Feldmann A, et al. From mono- to bivalent: improving theranostic properties of target modules for redirection of UniCAR T cells against EGFR-expressing tumor cells in vitro and in vivo. Oncotarget. 2018, 9(39):25597-25616. doi: 10.18632/oncotarget.25390.

Bachmann D, Aliperta R, Bergmann R, Feldmann A, Koristka S, Arndt C, et al. Retargeting of UniCAR T cells with an in vivo synthesized target module directed against CD19 positive tumor cells. Oncotarget. 2017, 9(7):7487-7500. doi: 10.18632/oncotarget.23556

Mitwasi N, Feldmann A, Bergmann R, Berndt N, Arndt C, Koristka S, et al. Development of novel target modules for retargeting of UniCAR T cells to GD2 positive tumor cells. Oncotarget. 2017, 8(65):108584-108603. doi: 10.18632/oncotarget.21017

Pishali Bejestani E, Cartellieri M, Bergmann R, Ehninger A, Loff S, Kramer M, et al. Characterization of a switchable chimeric antigen receptor platform in a pre-clinical solid tumor model. Oncoimmunlogy. 2017, e1342909. doi: 10.1080/2162402X.2017.1342909. 

Albert S, Arndt C, Feldmann A, Bergmann R, Bachmann D, Koristka S, et al. A novel nanobody-based target module for retargeting of T lymphocytes to EGFR-expressing cancer cells via the modular UniCAR platform. Oncoimmunlogy. 2017, 6(4): e1287246. doi: 10.1080/2162402X.2017.1287246. 

Feldmann A, Arndt C, Bergmann R, Loff S, Cartellieri M, Bachmann D, et al. Retargeting of T lymphocytes to PSCA- or PSMA positive prostate cancer cells using the novel modular chimeric antigen receptor platform technology “UniCAR”.  Oncotarget. 2017, 8(19):31368-31385; doi: 10.18632/oncotarget.15572

Bachmann D, Aliperta R, Bergmann R et al. Retargeting of UniCAR T cells with an in vivo synthesized target module directed against CD19 positive tumor cells. Oncotarget 2017. 9(7):7487-7500. doi: 10.18632/oncotarget.23556

Mitwasi N, Feldmann A, Bergmann R, Berndt N, Arndt C, Kosistka S, et a. Development of novel target modules for retargeting of UniCAR T cells to GD2-positive tumor cells. Oncotarget 2017; doi: 10.18632/oncotarget.21017. 

Dietrich J, Loff S, Meyer JE, von Bonin M, Hetzenecker M, Spehr J, et al. Targeting leukemia using an inducible universal chimeric antigen receptor (UniCAR) T cell technology. Cytotherapy 2017, 19(5), S9, Abstract.

Cartellieri M, Feldmann A, Koristka S, Arndt C, Loff S, Ehninger A, et al. Switching CAR T cells on and of: a novel modular platform for retargeting of T cells to AML blasts. Blood cancer J. 2016, 6(8):e458; doi: 10.1038/bcj.2016.61.

Loff S, von Bonin M, Dietrich J, Meyer JE, Feldmann A, Arndt C, et al. The UniCAR system: Inducible CAR T cells for precise reactivity and high efficacy against hematopoietic malignancies. Cancer Immunology Research. 2016, 4(11), DOI: 10.1158/2326-6066.IMM2016-B099, Abstract.

Cartellieri M, Loff S, von Bonin M, Bejestani EP, Ehninger E, Feldmann A, et al. UniCAR: A novel modular retargeting platform technology for CAR T cells. Blood 2015, 126: 5549, Abstract.

Cartellieri M, Koristka S, Arndt C, et al. A novel ex vivo isolation and expansion procedure for chimeric antigen receptor engrafted human T cells. PLoS One. 2014;9(4):e93745.

Koristka S; Cartellieri M; Feldmann A; Arndt C; Loff S; Michalk I, et al. Flexible antigen-specific redirection of human regulatory T cells via a novel universal chimeric antigen receptor system. Blood. 2014; 124:3494, Abstract.

Kloss CC, Condomines M, Cartellieri M, Bachmann M and Sadelain M. Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells. Nat. Biotechnol. 2013, 31:71-75.

Cartellieri M, Bachmann M, Feldmann A, et al. Chimeric antigen receptor-engineered T cells for immunotherapy of cancer. J Biomed Biotechnol. 2010;2010:956304.

Morgenroth A, Cartellieri M, Schmitz M, et al. Targeting of tumor cells expressing the prostate stem cell antigen (PSCA) using genetically engineered T-cells. Prostate. 67:1121-1131.

 

Publications on ATAC Platform

Fasslrinner F, Arndt C, Koristka S, Feldmann A, Altmann H, von Bonin M, et al. Midostaurin abrogates CD33-directed UniCAR and CD33-CD3 bispecific antibody therapy in acute myeloid leukaemia. Br J Haematol. 2019, doi: 10.1111/bjh.15975.

Aliperta R, Welzel P, Bergmann R, Freudenberg U, Berndt N, Feldmann A, et al. Cryogel-supported stem cell factory for customized sustained release of bispecific antibodies for cancer immunotherapy. Scientific Reports. 2017, doi: 10.1038/srep42855

Ehninger A, Cartellieri M, Feldmann A, Arndt C, Koristka S, Loff S, et al. Improved killing of tumor cells by a novel flexible antibody-based modular T cell retargeting system. Proceedings: AACR 107th Annual Meeting 2016; April 16-20, 2016; New Orleans, LA, Abstract 2313 doi: 10.1158/1538-7445.AM2016-2313

Aliperta R, Cartellieri M, Feldmann A, Arndt C, Koristka S, Michalk I, et al. Bispecific antibody releasing-mesenchymal stromal cell machinery for retargeting T cells towards acute myeloid leukemia blasts. Blood Cancer Journal. 2015 5, e348; doi:10.1038/bcj.2015.73

Arndt C, Feldmann A, von Bonin M, et al. Costimulation improves the killing capability of T cells redirected to tumor cells expressing low levels of CD33: description of a novel modular targeting system. Leukemia. 2014;28(1):59-69.

Koristka S, Cartellieri M, Arndt C, Bippes CC, Feldmann A, Michalk I, et al. Retargeting of regulatory T cells to surface-inducible autoantigen La/SS-B. J Autoimmun. 2013, 42:105-116.

Arndt C, von Bonin M, Cartellieri M, et al. Redirection of T cells with a first fully humanized bispecific CD33-CD3 antibody efficiently eliminates AML blasts without harming hematopoietic stem cells. Leukemia. 2013;27(4):964-967.

Stamova S, Feldmann A, Cartellieri M, et al. Generation of single-chain bispecific green fluorescent protein fusion antibodies for imaging of antibody-induced T cell synapses. Anal Biochem. 2012;423(2):261-268.

Koristka S, Cartellieri M, Theil A, et al. Retargeting of human regulatory T cells by single-chain bispecific antibodies. J Immunol. 2012;188(3):1551-1558.

Feldmann A, Arndt C, Topfer K, et al. Novel humanized and highly efficient bispecific antibodies mediate killing of prostate stem cell antigen-expressing tumor cells by CD8+ and CD4+ T cells. J Immunol. 2012;189(6):3249-3259.

Stamova S, Cartellieri M, Feldmann A, et al. Simultaneous engagement of the activatory receptors NKG2D and CD3 for retargeting of effector cells to CD33-positive malignant cells. Leukemia. 2011;25(6):1053-1056.

Stamova S, Cartellieri M, Feldmann A, et al. Unexpected recombinations in single chain bispecific anti-CD3-anti-CD33 antibodies can be avoided by a novel linker module. Mol Immunol. 2011;49(3):474-482

Feldmann A, Stamova S, Bippes CC, et al. Retargeting of T cells to prostate stem cell antigen expressing tumor cells: comparison of different antibody formats. Prostate. 2011;71(9):998-1011.

 
 

Read more about our Science

clinical and Pre-clinical pipeline Overview